James Mond

1.4k total citations
15 papers, 451 citations indexed

About

James Mond is a scholar working on Molecular Biology, Infectious Diseases and Immunology. According to data from OpenAlex, James Mond has authored 15 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Infectious Diseases and 4 papers in Immunology. Recurrent topics in James Mond's work include Streptococcal Infections and Treatments (3 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). James Mond is often cited by papers focused on Streptococcal Infections and Treatments (3 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). James Mond collaborates with scholars based in United States, Netherlands and Canada. James Mond's co-authors include S. M. Walsh, Eddy J. Smid, Igor Mierau, Kees Olieman, Gregory W. Siskind, Young Tai Kim, Iris van Swam, Benjamin N. Greener, Richard L. Wasserman and Kamaleshwar P. Singh and has published in prestigious journals such as The Journal of Immunology, Antimicrobial Agents and Chemotherapy and European Journal of Immunology.

In The Last Decade

James Mond

15 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Mond United States	9	217	96	96	78	73	15	451
Tomomitsu Sewaki Japan	9	241 1.1×	98 1.0×	84 0.9×	35 0.4×	38 0.5×	14	489
Melissa A. Lasaro United States	12	225 1.0×	90 0.9×	81 0.8×	162 2.1×	40 0.5×	14	653
Stacy M. Burns United States	7	228 1.1×	47 0.5×	39 0.4×	73 0.9×	28 0.4×	9	468
Anne N. Reid Canada	8	148 0.7×	70 0.7×	113 1.2×	53 0.7×	20 0.3×	9	361
WENDY O. HUFNAGLE United States	7	257 1.2×	203 2.1×	31 0.3×	80 1.0×	48 0.7×	9	487
Donna L. Hartley United States	8	451 2.1×	72 0.8×	53 0.6×	164 2.1×	38 0.5×	9	663
Debora Barnett Foster Canada	15	265 1.2×	201 2.1×	138 1.4×	123 1.6×	22 0.3×	28	712
Alice C. L. Len Australia	9	271 1.2×	74 0.8×	98 1.0×	63 0.8×	18 0.2×	9	546
Pascale Kharrat France	7	294 1.4×	138 1.4×	232 2.4×	134 1.7×	51 0.7×	9	669
Vengadesan Krishnan India	15	545 2.5×	122 1.3×	78 0.8×	44 0.6×	66 0.9×	40	803

Countries citing papers authored by James Mond

Since Specialization

Citations

This map shows the geographic impact of James Mond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Mond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Mond more than expected).

Fields of papers citing papers by James Mond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Mond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Mond. The network helps show where James Mond may publish in the future.

Co-authorship network of co-authors of James Mond

This figure shows the co-authorship network connecting the top 25 collaborators of James Mond. A scholar is included among the top collaborators of James Mond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Mond. James Mond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Mond, James, Jesse Papenburg, Guy Boivin, et al.. (2023). In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections. Virology. 586. 115–121. 1 indexed citations

Bu, Wei, Sohtaro Mine, Zeshan Tariq, et al.. (2021). Epstein-Barr virus (EBV) hyperimmune globulin isolated from donors with high gp350 antibody titers protect humanized mice from challenge with EBV. Virology. 561. 80–86. 4 indexed citations

Wasserman, Richard L., et al.. (2019). Manufacturing Process Optimization of ADMA Biologics’ Intravenous Immunoglobulin Products, BIVIGAM ^® and ASCENIV™. Immunotherapy. 11(16). 1423–1433. 8 indexed citations

Wasserman, Richard L., Benjamin N. Greener, & James Mond. (2017). RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations. Expert Review of Clinical Immunology. 13(12). 1107–1119. 21 indexed citations

Mond, James. (2015). RESULTS OF A PHASE III TRIAL IN PATIENTS WITH PIDD USING AN IVIG CONTAINING HIGH TITER NEUTRALIZING ANTIBODY TO RESPIRATORY SYNCYTIAL VIRUS ( RSV). 1 indexed citations

Mierau, Igor, et al.. (2005). Industrial-scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE: The case of lysostaphin. Microbial Cell Factories. 4(1). 15–15. 93 indexed citations

Mierau, Igor, Kees Olieman, James Mond, & Eddy J. Smid. (2005). Optimization of the Lactococcus lactis nisin-controlled gene expression system NICE for industrial applications. Microbial Cell Factories. 4(1). 16–16. 97 indexed citations

Walsh, S. M., et al.. (2004). Extended Nasal Residence Time of Lysostaphin and an Anti-Staphylococcal Monoclonal Antibody by Delivery in Semisolid or Polymeric Carriers. Pharmaceutical Research. 21(10). 1770–1775. 15 indexed citations

Mond, James, et al.. (2004). Lysostaphin-Coated Catheters Eradicate Staphylococccus aureus Challenge and Block Surface Colonization. Antimicrobial Agents and Chemotherapy. 48(7). 2704–2707. 57 indexed citations

10.

Walsh, S. M., et al.. (2003). Improved Pharmacokinetics and Reduced Antibody Reactivity of Lysostaphin Conjugated to Polyethylene Glycol. Antimicrobial Agents and Chemotherapy. 47(2). 554–558. 89 indexed citations

11.

Mond, James, Kamaleshwar P. Singh, & Deodutta Roy. (2001). The biphasic stimulation of proliferation of Leydig cells by estrogen exposure. International Journal of Oncology. 18(3). 623–8. 13 indexed citations

12.

Brunswick, Mark, Ezio Bonvini, Mark L. Francis, et al.. (1990). Absence of demonstrable phospholipid turnover in B cells stimulated by low mitogenic concentrations of dextran‐anti‐immunoglobulin conjugates. European Journal of Immunology. 20(4). 855–861. 8 indexed citations

13.

Rothstein, Thomas L., Michael G. Mage, James Mond, & Louise McHugh. (1978). Guinea Pig Antiserum to Mouse Cytotoxic T Lymphocytes and Their Precursors. The Journal of Immunology. 120(1). 209–215. 6 indexed citations

14.

Mond, James, Young Tai Kim, & Gregory W. Siskind. (1974). Studies on the Control of Antibody Synthesis. The Journal of Immunology. 112(3). 1255–1263. 15 indexed citations

15.

Mond, James, Young Tai Kim, & Gregory W. Siskind. (1974). Studies on the control of antibody synthesis. V. Effect of nonspecific modification of the magnitude of the immune response on the affinity of the antibody synthesized.. PubMed. 112(3). 1255–63. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact